Literature DB >> 2830015

Epidermal growth factor receptor expression in human lung cancer cell lines.

M Haeder1, M Rotsch, G Bepler, C Hennig, K Havemann, B Heimann, K Moelling.   

Abstract

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines were studied for epidermal growth factor (EGF) receptor expression. All NSCLC cell lines tested (eight of eight) had specific EGF binding sites, whereas only five of 11 SCLC cell lines bound EGF. NSCLC and SCLC cell lines expressed the same type of high affinity EGF binding sites with a Kd of 0.5 to 4.5 nM; however, NSCLC cells bound significantly more EGF than SCLC cell lines. The amount of binding sites in NSCLC cells ranged between 71 and 1,000 fmol/mg of protein and in SCLC cells, between 26 and 143 fmol/mg of protein. The two SCLC cell lines with EGF binding values within the range of NSCLC belonged to the variant subtype of SCLC. By means of an anti-erbB serum and indirect radioimmunoprecipitation, a strong Mr approximately 170,000 protein band could be detected in the NSCLC cell lines. This protein corresponds to the EGF receptor molecule. Its identity was proven by competition with excess erbB antigen for the antibody during the radioimmunoprecipitation. Furthermore, this Mr 170,000 protein exhibited protein kinase activity as evidenced by in vitro autophosphorylation. The radioactivity incorporated into the Mr 170,000 band in radioimmunoprecipitation and protein kinase assays was 10 to 100 times lower in these SCLC cell lines which were positive in the EGF binding assay compared to the NSCLC cell lines. We conclude that NSCLC in contrast to SCLC expresses high levels of EGF receptors which may be used to facilitate the differential diagnosis in some cases of lung cancer. These data suggest that EGF may play a role in growth and differentiation of NSCLC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830015

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

Review 2.  Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.

Authors:  Josephine Chou; Yu-Ching Lin; Jae Kim; Liang You; Zhidong Xu; Biao He; David M Jablons
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

3.  Epidermal growth factor receptor in adenocarcinoma of the kidney.

Authors:  K E Ambs; A Takahashi; F Hering; S Costa; P R Huber
Journal:  Urol Res       Date:  1989

4.  Polydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapy.

Authors:  Kvar C L Black; Ji Yi; José G Rivera; Daria C Zelasko-Leon; Phillip B Messersmith
Journal:  Nanomedicine (Lond)       Date:  2012-08-14       Impact factor: 5.307

5.  Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor.

Authors:  R N Jorissen; V C Epa; H R Treutlein; T P Garrett; C W Ward; A W Burgess
Journal:  Protein Sci       Date:  2000-02       Impact factor: 6.725

6.  The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors.

Authors:  J Bergh
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

7.  Epidermal growth factor receptor and lipid membrane components in human lung cancers.

Authors:  A Di Carlo; A Mariano; P E Macchia; C Cecere; G Ferrante; V Macchia
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

8.  Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb.

Authors:  M Caraglia; P Tagliaferri; P Correale; G Genua; A Pinto; S Del Vecchio; G Esposito; A R Bianco
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

9.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

10.  Biological disposition of intravenously administered 131I-labeled anti-EGF-receptor antibody (RG 83852) in the rat.

Authors:  V K Khetarpal; L S Storbeck
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.